摘要
目的探究索利那新对膀胱过度活动症(overactive bladder,OAB)病人逼尿肌功能及预后的影响。方法 OAB病人128例,根据不同的治疗方法分为对照组与研究组,每组各64例。对照组采用托特罗定治疗,研究组采用索利那新治疗,服药时间为8周。比较两组病人尿动力参数、膀胱过度活动症症状评分(overactive bladder symptom score,OABSS)以及不良反应情况。结果研究组服药后膀胱顺应性、逼尿无抑制收缩次数、膀胱初次排尿感、最大膀胱容量、最大尿流率分别为(53.1±26.4)ml/cm H2O、(1.5±1.2)次、(177.0±88.0)ml、(298.0±88.0)ml和(53.4±17.1)ml/s,对照组分别为(58.2±29.5)ml/cm H2O、(1.9±1.5)次、(155.0±90.0)ml、(275.0±98.0)ml和(54.0±20.1)ml/s,两组比较差异有统计学意义(P<0.05)。研究组和对照组服药后OABSS评分分别为(5.9±2.4)分和(6.7±3.4)分,差异有统计学意义(P<0.05)。研究组不良发生率为4.6%,对照组为14.0%,差异有统计学意义(P<0.05)。结论索利那新对治疗OAB,临床效果满意,不良反应轻微。
Objective To investigate the effect of Solifenacin on detrusor function and prognosis in patients with overactive bladder.Methods 128 cases of patients with overactive bladder admitted to our hospital from March 2016 to December 2018 were selected,and 64 cases were divided into control group and research group according to different treatment methods.The control group was treated with trotrodine and the research group with Solifenacin.The clinical efficacy of the two groups was compared and analyzed.Results The bladder compliance of the study group,the number of bladder compression inhibition,the initial bladder urination,the maximum bladder volume,and the maximum urine flow rate[(53.1±26.4)ml/cm H2O,(1.5±1.2)times,(177.0±88.0)ml,(298.0±88.0)ml,(53.4±17.1)ml/s]was significantly better than the control group[(58.2±29.5)ml/cm H2O,(1.9±1.5)times,(155.0±90.0)ml,(275.0±98.0)ml,(54.0±20.1)ml/s,and the difference was statistically significant(P<0.05).The OABSS score(5.9±2.4)scores of the study group before and after medication were better than the control group(6.7±3.4),and the difference was statistically significant(P<0.05).The incidence of adverse events in the study group was 4.6%significantly lower than that in the control group(14.0%),and the difference was statistically significant(P<0.05).Conclusion The use of solifenacin for the treatment of OAB patients,the clinical results are satisfactory,the adverse reactions are mild,it is worthy of clinical use.
作者
孔令军
赵佳龙
KONG Lingjun;ZHAO Jialong(Department of Urology,Southern County People's Hospital,Sichuan Province,Nanbu 637300,China)
出处
《临床外科杂志》
2019年第9期798-800,共3页
Journal of Clinical Surgery
